<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eye involvement in <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) is frequent and an important cause of morbidity </plain></SENT>
<SENT sid="1" pm="."><plain>The mean age at <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0000554'>uveitis</z:hpo> is between 20 and 30 years in male and 30 years in female patients </plain></SENT>
<SENT sid="2" pm="."><plain>Ocular involvement includes anterior, posterior or <z:hpo ids='HP_0012121'>panuveitis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000554'>Uveitis</z:hpo> may be the presenting manifestation of the disease in 20% of cases or may appear 2 or 3 years after the disease <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The estimated risk of <z:hpo ids='HP_0000618'>blindness</z:hpo> at 5 years ranges from 15 to 25% </plain></SENT>
<SENT sid="5" pm="."><plain>The main goals in the management of patients with BD <z:hpo ids='HP_0000554'>uveitis</z:hpo> are the rapid control of intraocular <z:mp ids='MP_0001845'>inflammation</z:mp>, the prevention of recurrent attacks, the achievement of complete remission, and preservation of vision </plain></SENT>
<SENT sid="6" pm="."><plain>The medical treatment of patients with severe <z:hpo ids='HP_0000554'>uveitis</z:hpo> relies on the use of systemically administered drugs, including <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and cytotoxic agents </plain></SENT>
<SENT sid="7" pm="."><plain>Anti-TNF agents and interferon-alpha seem to be efficient and well-tolerated alternative therapeutic options </plain></SENT>
<SENT sid="8" pm="."><plain>Controlled clinical trials are mandatory to define the place of these new immunomodulatory agents in the therapeutic strategy, and especially their use as first-line therapy </plain></SENT>
</text></document>